Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Recruiting · NCT04519151 · Registry updated 2023-06-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian epithelial tumor, stomach disorder | Recruiting | Phase 2 | 2023-06-08 | NCT04519151 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sheba Medical Center | 63 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sheba Medical Center | Ramat Gan | Israel | 43 |